GR1004470B - Methods of composition of complex compounds of vanadium (iii) with the sulfrydyl compounds (-sh, thiols) cystein (h2cys) and n-(2-mercaptoptoprorionyl)-glycine for the production of concoctions for the therapy of the diabetes and virulent diseases of ... - Google Patents
Methods of composition of complex compounds of vanadium (iii) with the sulfrydyl compounds (-sh, thiols) cystein (h2cys) and n-(2-mercaptoptoprorionyl)-glycine for the production of concoctions for the therapy of the diabetes and virulent diseases of ...Info
- Publication number
- GR1004470B GR1004470B GR20000100227A GR2000100227A GR1004470B GR 1004470 B GR1004470 B GR 1004470B GR 20000100227 A GR20000100227 A GR 20000100227A GR 2000100227 A GR2000100227 A GR 2000100227A GR 1004470 B GR1004470 B GR 1004470B
- Authority
- GR
- Greece
- Prior art keywords
- vanadium
- cystein
- diabetes
- body weight
- virulent diseases
- Prior art date
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
rganic and inorganic compounds of vanadium have been successfully used for the treatment of diabetes and virulent diseases. Int he present invention. The composition of three new vanadium (III) complexes is described, one with aminoacid cystein, one with the pseudopeptide N-(2-mercaptopropionyl)-glycine and their therapeutic activity for the treatment of diabetes and virulent diseases.The above complexes were tested to rats that were provided with alloxane for becoming diabetic and with benzopyrene for inducing cancer formation, in daily doses of 0.5 mg V/kg body weight provided orally. Furthermore, the toxicity of the complex of V-cystein was tested with the provision of a dose of 18 mg V/kg body weight orally.The results have shown that the reange of therapeutic treatment of both complexes starts from daily doses of 0,5 mg V/kg body weight and is very satisfactory in doses of 5 kg V/kg body weight for both nosological entities. The results also showed that for virulent diseases, treatment with the vanadium -cystein complex is also more effective and exhibits no toxicity, even for daily doses of 18 mg vanadium per body weight. From the above it derives that the preparation of these complexes and their oral or other provision in non-toxic concentrations is effective for the therapy of diabetes and virulent diseases in humans.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GR20000100227A GR1004470B (en) | 2000-07-07 | 2000-07-07 | Methods of composition of complex compounds of vanadium (iii) with the sulfrydyl compounds (-sh, thiols) cystein (h2cys) and n-(2-mercaptoptoprorionyl)-glycine for the production of concoctions for the therapy of the diabetes and virulent diseases of ... |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GR20000100227A GR1004470B (en) | 2000-07-07 | 2000-07-07 | Methods of composition of complex compounds of vanadium (iii) with the sulfrydyl compounds (-sh, thiols) cystein (h2cys) and n-(2-mercaptoptoprorionyl)-glycine for the production of concoctions for the therapy of the diabetes and virulent diseases of ... |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| GR20000100227A GR20000100227A (en) | 2002-03-29 |
| GR1004470B true GR1004470B (en) | 2004-03-04 |
Family
ID=10944318
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GR20000100227A GR1004470B (en) | 2000-07-07 | 2000-07-07 | Methods of composition of complex compounds of vanadium (iii) with the sulfrydyl compounds (-sh, thiols) cystein (h2cys) and n-(2-mercaptoptoprorionyl)-glycine for the production of concoctions for the therapy of the diabetes and virulent diseases of ... |
Country Status (1)
| Country | Link |
|---|---|
| GR (1) | GR1004470B (en) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2619382B1 (en) * | 1987-08-11 | 1990-05-04 | Lazaro Rene | ORGANO-MINERAL VANADYL COMPOUND, PROCESS FOR OBTAINING SUCH A COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING THIS ORGANO-MINERAL COMPOUND |
| JPH02292217A (en) * | 1989-05-08 | 1990-12-03 | Otsuka Pharmaceut Co Ltd | Treating agent for diabetes |
| WO2000024730A1 (en) * | 1998-10-28 | 2000-05-04 | The University Of British Columbia | Organic vanadium(iii) complexes and their use |
-
2000
- 2000-07-07 GR GR20000100227A patent/GR1004470B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GR20000100227A (en) | 2002-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG166294G (en) | Inhalation medicaments for treating respiratory disorders | |
| JP2001522892A (en) | 9-Deoxy-2 ′, 9-α-methano-3-oxa-4,5,6-trinol-3,7- (1 ′, 3′-interphenylene) -13,14 for treatment of peripheral vascular disease -Use of dihydro-prostaglandin F1 | |
| HK1059564A1 (en) | Indanylderivatives for treating airway diseases | |
| BG106251A (en) | Levodopa (carbidopa) entacapone pharmaceutical preparation | |
| NZ527113A (en) | Rapid-onset medicament for the treatment of sexual dysfunction | |
| TW200607510A (en) | Use of optically pure (s.s)-reboxetine in the manufacture of a medicament for the treatment or prevention of fibromyalgia or another somatoform disorder | |
| JP2002521428A5 (en) | ||
| GB8623557D0 (en) | Therapeutic agents | |
| JP2002528502A5 (en) | ||
| BG105173A (en) | Novel salt form of pantoprazole | |
| GB2235626B (en) | Inhalation medicaments for treating respiratory disorders | |
| AP1849A (en) | Dosage regimen and pharmaceutical composition for emergency contraception | |
| GR3035402T3 (en) | Use of incense in the treatment of alzheimer's disease | |
| IL150817A0 (en) | Pyrrole-type compounds, compositions, and methods for treating cancer or viral diseases | |
| GR3036774T3 (en) | Compositions containing G-CSF and TNF binding protein. | |
| CA2038744A1 (en) | Pharmaceutical composition containing slightly water-soluble drug | |
| EP1254658A4 (en) | Remedies | |
| JP2003514025A5 (en) | ||
| OA07029A (en) | Gallium chloride, a new anti-cancer drug. | |
| WO2000066550A8 (en) | New compounds | |
| GR1004470B (en) | Methods of composition of complex compounds of vanadium (iii) with the sulfrydyl compounds (-sh, thiols) cystein (h2cys) and n-(2-mercaptoptoprorionyl)-glycine for the production of concoctions for the therapy of the diabetes and virulent diseases of ... | |
| NZ303993A (en) | Pharmaceutical compositions containing aminotetralin derivatives for treating cardiac disorders | |
| WO1996030016A3 (en) | Low dose ridogrel formulations and their use for the treatment of inflammatory bowel diseases | |
| WO2001068076A8 (en) | D-enantiomer of dfmo and methods of use thereof for treating cancer | |
| JP2627914B2 (en) | Selective enhancer of prostaglandins |